Zobrazeno 1 - 10
of 100
pro vyhledávání: '"Elad Jacoby"'
Autor:
Ohad Benjamini, Shalev Fried, Roni Shouval, Jessica R. Flynn, Ofrat Beyar-Katz, Lori A Leslie, Tsilla Zucherman, Ronit Yerushalmi, Noga Shem-Tov, Maria Lia Palomba, Ivetta Danylesko, Inbal Sdayoor, Hila Malka, Orit Itzhaki, Hyung Suh, Sean M. Devlin, Ronit Marcus, Parastoo B Dahi, Elad Jacoby, Gunjan L Shah, Craig S Sauter, Andrew Ip, Miguel-Angel Perales, Arnon Nagler, Avichai Shimoni, Michael Scordo, Abraham Avigdor
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The activity of anti-CD19 CAR T cell therapy in chronic lymphocytic leukemia (CLL) with Richter's transformation (RT) to aggressive large B cell lymphoma (LBCL) is largely unknown. In a multicenter retrospective study, we report the safety and effica
Externí odkaz:
https://doaj.org/article/446c107a98b1415f962e7e3be018edfa
Autor:
Ivetta Danylesko, Noga Shem-Tov, Ronit Yerushalmi, Elad Jacoby, Amos Toren, Orit Itzhaki, Roni Shouval, Avichai Shimoni, Avigdor Abraham, Arnon Nagler
Publikováno v:
HemaSphere, Vol 7, p e4369964 (2023)
Externí odkaz:
https://doaj.org/article/e68ac14296cc471fad149493a36eb6c7
Autor:
Elad Jacoby, Moriya Ben Yakir-Blumkin, Shiri Blumenfeld-Kan, Yehuda Brody, Amilia Meir, Naomi Melamed-Book, Tina Napso, Gat Pozner, Esraa Saadi, Ayelet Shabtay-Orbach, Natalie Yivgi-Ohana, Noa Sher, Amos Toren
Publikováno v:
npj Regenerative Medicine, Vol 6, Iss 1, Pp 1-12 (2021)
Abstract Mitochondria are cellular organelles critical for numerous cellular processes and harboring their own circular mitochondrial DNA (mtDNA). Most mtDNA associated disorders (either deletions, mutations, or depletion) lead to multisystemic disea
Externí odkaz:
https://doaj.org/article/ea28dd8efa07497c88f0f158a175ba5b
Autor:
Karin Brezinger-Dayan, Orit Itzhaki, Jenny Melnichenko, Adva Kubi, Li-at Zeltzer, Elad Jacoby, Abraham Avigdor, Ronnie Shapira Frommer, Michal J. Besser
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Adoptive cell therapy with chimeric antigen receptor (CAR) T cells has become an efficient treatment option for patients with hematological malignancies. FDA approved CAR T products are manufactured in centralized facilities from fresh or frozen leuk
Externí odkaz:
https://doaj.org/article/28b30e0dcb6a46629daeb2902aaf9cab
Publikováno v:
American Journal of Ophthalmology Case Reports, Vol 24, Iss , Pp 101223- (2021)
A unique image of anterior chamber infiltration in a 2-year-infant with leukemia, treated with CD19 CAR T cells. Despite significant lymphopenia and resemblance of fungal infection initially, biopsy and cytologic analysis from anterior chamber fluid
Externí odkaz:
https://doaj.org/article/b905cff2cf314cb585f28a038157cbdd
Autor:
Ronnie Shapira-Frommer, Elad Jacoby, Orit Itzhaki, Abraham Nissani, Gal Markel, Jacob Schachter, Shaked Lev-Ari, Tomer Meirson, Nethanel Asher, Guy Ben-Betzalel, Michal J. Besser
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Adoptive cell therapy with T cells genetically engineered to express a chimeric antigen receptor (CAR-T) or tumor-infiltrating T lymphocytes (TIL) demonstrates impressive clinical results in patients with cancer. Lymphodepleting preconditi
Externí odkaz:
https://doaj.org/article/b123a9cc796845809ac8adf818ec97d0
Autor:
Katia Beider, Orit Itzhaki, Jacob Schachter, Ania Hava Grushchenko-Polaq, Valeria Voevoda-Dimenshtein, Evgenia Rosenberg, Olga Ostrovsky, Olivia Devillers, Ronnie Shapira Frommer, Li-at Zeltzer, Amos Toren, Elad Jacoby, Avichai Shimoni, Abraham Avigdor, Arnon Nagler, Michal J. Besser
Publikováno v:
Cells, Vol 11, Iss 7, p 1140 (2022)
Despite the high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, its full capacity is currently limited by the generation of dysfunctional CAR T cells. Senescent or exhausted CAR T cells possess poor targeting an
Externí odkaz:
https://doaj.org/article/02514ef3cdbe4b41b2bc1bbc9123ee34
Autor:
Meir Rozenbaum, Amilia Meir, Yarden Aharony, Orit Itzhaki, Jacob Schachter, Ilan Bank, Elad Jacoby, Michal J. Besser
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Autologous T cells engineered to express a chimeric antigen receptor (CAR) against the CD19 antigen are in the frontline of contemporary hemato-oncology therapies, leading to high remission rates in B-cell malignancies. Although effective, major obst
Externí odkaz:
https://doaj.org/article/8067043762c649a48b16f18b0e8d3ff8
Autor:
Elad Jacoby
Publikováno v:
Clinical Hematology International, Vol 1, Iss 2 (2019)
Application of immunotherapeutic modalities changed paradigms in the treatment of hematologic malignancies, with regards to drug manufacturing, treatment protocols, short- and long-term toxicities. FDA-approved therapies, including blinatumomab, tisa
Externí odkaz:
https://doaj.org/article/faa6cd51b2e949269324b56a02f61237
Autor:
Elad Jacoby, Sang M. Nguyen, Thomas J. Fountaine, Kathryn Welp, Berkley Gryder, Haiying Qin, Yinmeng Yang, Christopher D. Chien, Alix E. Seif, Haiyan Lei, Young K. Song, Javed Khan, Daniel W. Lee, Crystal L. Mackall, Rebecca A. Gardner, Michael C. Jensen, Jack F. Shern, Terry J. Fry
Publikováno v:
Nature Communications, Vol 7, Iss 1, Pp 1-10 (2016)
CAR-T targeting CD19 have been successfully used in a variety of B-cell malignancies but patients may eventually relapse. Here, the authors show that CD19 CAR-T resistance in pre-B cell ALL can be due to the induction of a myeloid lineage switch thro
Externí odkaz:
https://doaj.org/article/97b2ab47d3724d76ba75fa902257a2ba